NRAS and Miyoshi myopathy: Since NRAS mutations are found in 18% of MM and are furthermore observed as an escape mechanism against first-line vemurafenib treatment in BRAF-mutant MM, MEK-inhibition could represent a promising therapeutic target to enhance the susceptibility of melanoma cells to therapy-induced DNA damage.